Literature DB >> 21827850

Bone, joint and tooth development in mucopolysaccharidoses: relevance to therapeutic options.

E Oussoren1, M M M G Brands, G J G Ruijter, A T van der Ploeg, A J J Reuser.   

Abstract

The mucopolysaccharidoses (MPS) are prominent among the lysosomal storage diseases. The intra-lysosomal accumulation of glycosaminoglycans (GAGs) in this group of diseases, which are caused by several different enzyme deficiencies, induces a cascade of responses that affect cellular functions and maintenance of the extra-cellular matrix. Against the background of normal tissue-specific processes, this review summarizes and discusses the histological and biochemical abnormalities reported in the bones, joints, teeth and extracellular matrix of MPS patients and animal models. With an eye to the possibilities and limitations of reversing the pathological changes in the various tissues, we address therapeutic challenges, and present a model in which the cascade of pathologic events is depicted in terms of primary and secondary events. 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21827850     DOI: 10.1016/j.bbadis.2011.07.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  35 in total

1.  Epiphyseal hyperplasia caused by an ectopic ossification center of the distal tibia: presentation of a pediatric case with 13 years of radiological surveillance.

Authors:  Susanne Scheipl; Stefan Tauber; Marko Bergovec; Andreas Leithner; Gerhard Ranner
Journal:  Skeletal Radiol       Date:  2018-02-09       Impact factor: 2.199

Review 2.  Hurdles in treating Hurler disease: potential routes to achieve a "real" cure.

Authors:  Brigitte T A van den Broek; Jaap van Doorn; Charlotte V Hegeman; Stefan Nierkens; Caroline A Lindemans; Nanda Verhoeven-Duif; Jaap Jan Boelens; Peter M van Hasselt
Journal:  Blood Adv       Date:  2020-06-23

3.  Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI.

Authors:  Lynda E Polgreen; Richard K Vehe; Kyle Rudser; Alicia Kunin-Batson; Jeanine Jarnes Utz; Patricia Dickson; Elsa Shapiro; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2016-01-28       Impact factor: 4.797

4.  Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey.

Authors:  Marion M G Brands; Deniz Güngör; Johanna M P van den Hout; Francois P J Karstens; Esmee Oussoren; Iris Plug; Jaap Jan Boelens; Peter M van Hasselt; Carla E M Hollak; Margot F Mulder; Estela Rubio Gozalbo; Jan A Smeitink; G Peter A Smit; Frits A Wijburg; Hanka Meutgeert; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-07-22       Impact factor: 4.982

5.  Isokinetic muscle strength differences in patients with mucopolysaccharidosis I, II, and VI.

Authors:  Natalie E Taylor; Donald R Dengel; Troy C Lund; Kyle D Rudser; Paul J Orchard; Julia Steinberger; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

6.  Growth patterns in children with mucopolysaccharidosis I and II.

Authors:  Agnieszka Różdżyńska-Świątkowska; Agnieszka Jurecka; Joachim Cieślik; Anna Tylki-Szymańska
Journal:  World J Pediatr       Date:  2014-11-20       Impact factor: 2.764

7.  Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.

Authors:  Joseph A Chiaro; Patricia O'Donnell; Eileen M Shore; Neil R Malhotra; Katherine P Ponder; Mark E Haskins; Lachlan J Smith
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

8.  Postnatal progression of bone disease in the cervical spines of mucopolysaccharidosis I dogs.

Authors:  Joseph A Chiaro; Matthew D Baron; Chelsea M Del Alcazar; Patricia O'Donnell; Eileen M Shore; Dawn M Elliott; Katherine P Ponder; Mark E Haskins; Lachlan J Smith
Journal:  Bone       Date:  2013-04-04       Impact factor: 4.398

9.  Genistein increases glycosaminoglycan levels in mucopolysaccharidosis type I cell models.

Authors:  Sandra D K Kingma; Tom Wagemans; Lodewijk IJlst; Frits A Wijburg; Naomi van Vlies
Journal:  J Inherit Metab Dis       Date:  2014-04-04       Impact factor: 4.982

10.  Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).

Authors:  Molly Stapleton; Francyne Kubaski; Robert W Mason; Hiromasa Yabe; Yasuyuki Suzuki; Kenji E Orii; Tadao Orii; Shunji Tomatsu
Journal:  Expert Opin Orphan Drugs       Date:  2017-03-08       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.